S
Mark Stejbach
VP, Managed Care Marketing, Merck
DOUBLE DUTY: Is helping build Merck's new healthcare model
OF NOTE: First non-finance person to run Merck's investor relations
On payers:
For many years, the success of the industry was at least in part driven by the inefficiency of the economic model of healthcare. In the short term, there's always more to be eked out from the current model—and I think some companies are going to run with that as hard and as long as they can. But in the long term, companies have to understand that the market is going to be increasingly influenced by the people who pay the bills—payers and consumers. In that way, pharma will start to become more like most other industries.
Mark Stejbach
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.